2022
Authors: CM Williams PCM, Qazi SA, Agarwal R, Velaphi S, Bielicki JA, Nambiar S, Giaquinto C, Bradley J, Noel GJ, Ellis S, O’Brien S, Balasegaram M & Sharland M
Published in: Bulletin of the World Health Organization
2021
Authors: Hill L.F, Clements M.N, Turner M.A, Donà D, Lutsar I, Jacqz-Aigrain E, Heath P.T, Roilides E, Rawcliffe L, Alonso-Diaz C, Baraldi E, Dotta A, Ilmoja M, Mahaveer A, Metsvaht T, Mitsiakos G, Papaevangelou V, Sarafidis K, Walker A.S, Sharland M, on behalf of the NeoVanc Consortium
Published in: The Lancet
2021
Authors: G. A. Levine, M. Sharland, S. Ellis, Y. Ferrisse, C. Loze, Y. Hsia, G. Fink, J. Bielicki; for the PediCAP project
Published in: ECCMID 2021
Abstract
Background: Amoxicillin and co-amoxiclav are commonly used antibiotics for community-acquired infections in young children. Both are classified as Access antibiotics for pediatric respiratory infections in the WHO EMLc.
2021
Authors: Phoebe C M Williams, John Bradley, Emmanuel Roilides, Linus Olson, Sheldon Kaplan, Irja Lutsar, Carlo Giaquinto, Daniel K Benjamin, Mike Sharland
Published in: The Lancet
Introduction: Antimicrobial resistance represents a substantial threat to the Sustainable Development Goals (SDGs), with a large impact on the health of children worldwide. However, very few paediatric trials for new antibiotics have been done to inform the optimal treatment of multidrug-resistant infections in children.
2020
Authors: Li G, Jackson C, Bielicki J, Ellis S, Hsiac Y, Sharland M
Published in: Bulletin of the World Health Organization, July 2020
Objective To investigate international consumption patterns of child-appropriate oral formulations of antibiotics by formulation type, with a focus on dispersible tablets, using data from a global sales database.
Methods Antibiotic sales data for 2015 covering 74 countries and regional country groups were obtained from the MIDAS® pharmaceutical sales database,
2020
Authors: Mathur S, Jackson C, Urus H, Ziarko I, Goodbun M, Hsia Y, Ellis S, Sharland M.
Published in: Bulletin of the World Health Organization, April 2020
Objective To compare dosing guidance in the paediatric formularies of high-income countries and emerging economies for 32 commonly prescribed antibiotics on the World Health Organization’s (WHO’s) 2017 Model List of Essential Medicines for Children.
2020
Authors: L. Hill, E. Jacqz-Aigrain, V. Elie, W. Zhao, M. Clements, M. Turner, I. Lutsar, P. Heath, E. Roilides, S. Walker, M. Sharland
Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020
2020
Authors: L. Hill, M. Clements, M. Turner, I. Lutsar, E. Jacqz-Aigrain, P. Heath, E. Roilides, S. Walker, M. Sharland
Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020
2020
Authors: E. Barbieri, D. Bottigliengo, P. Costenaro, A. Marzollo, M. Petris, M. Pierobon, G. Biddeci, C. Giaquinto, A. Biffi, D. Donà
Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020
Background: Febrile neutropenia (FN) is an acute potentially life-threatening oncological complication which should be treated promptly with antibiotics. With the spread of antibiotic resistance,
2020
Authors: P. Costenaro, A. Cantarutti, E. Barbieri, A. Scamarcia, A. Oletto, P. Sacerdoti, R. Lundin, L. Cantarutti, C. Giaquinto, D. Dona’
Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020
Background: Despite national and international efforts to promote appropriate antibiotic prescribing, Italian paediatric antimicrobial prescription rates are among the highest in Europe,
2020
Authors: Hill LF, Turner MA, Lutsar I, et al; NeoVanc Consortium.
Published in: Trials. 2020;21(1):329
2020
Authors: Donà D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M
Published in: Antimicrob Resist Infect Control.2020;9:3
Background Antibiotics are the most common medicines prescribed to children in hospitals and the community, with a high proportion of potentially inappropriate use. Antibiotic misuse increases the risk of toxicity, raises healthcare costs, and selection of resistance.
2019
Authors: Folgori L, Lutsar I, Standing JF, et al.
Published in: BMJ Open. 2019; 9:e032592
2019
Authors: Li G, Bielicki JA, Ahmed ASMNU, et al.
Published in: Arch Dis Child.2091;0:1-6
2019
Authors:Simitsopoulou M, Kadiltzoglou P, Kyrpitzi D, Roilides E.
Published in: Int J Biol Med Res.2019;10(1):6591-6596
Abstract This study aimed to compare the effects of vancomycin, linezolid and daptomycin against planktonic cells and biofilms of 32 bloodstream isolates derived from neonates and adults of three hospitals. Staphylococcus epidermidis biofilm formation was spectrophotometrically assessed following safranin staining.
2019
Authors: Jacqz-Aigrain E, Leroux S, Thomson AH, et al.
Published in: J Antimicrob Ther 2019; 74(8):2128-2138
2019
Authors: Hsia Y, Lee BR, Versporten A, et al; GARPEC and Global-PPS networks.
Published in: Lancet Glob Health. 2019;7(7):e861-e871
Background Improving the quality of hospital antibiotic use is a major goal of WHO’s global action plan to combat antimicrobial resistance. The WHO Essential Medicines List Access, Watch, and Reserve (AWaRe) classification could facilitate simple stewardship interventions that are widely applicable globally.
2019
Authors: Balasegaram M, Pécoul B, Gray G, Sharland M, Swaminathan S.
Published in: Lancet Infect Dis. 2019;19(6):573-574
Abstract Newborn babies, infants, and children are substantially affected by antimicrobial resistance. Globally, infectious diseases remain a major cause of morbidity and mortality in children, and an estimated 214 000 newborn babies died from drug-resistant bacterial infections in 2015
2019
Authors: O’Brien S, Sharland M, Zaoutis T
Published in: AMR CONTROL 2019-2020; online edition
Abstract It is time to prioritize children’s needs in the context of antimicrobial resistance (AMR). Children, especially babies and young infants, are particularly vulnerable to the rise in drug-resistant infection and need treatments that are adapted to their specific needs. Yet, there are almost no clinical trials looking into children’s antibiotics.
2019
Authors: Thomas R, Velaphi S, Ellis S, et al.
Published in: Expert Opin Pharmacother. 2019;20(4):415-422.
Introduction The incidence of healthcare-associated multidrug resistant bacterial infections, particularly due to carbapenem resistant organisms, has been on the rise globally. Among these are the carbapenem resistant Acinetobacter baumannii and Enterobacteriaceae, which have been responsible for numerous outbreaks in neonatal units.
2019
Authors: Donà D, Luise D, La Pergola E, et al.
Published in: Antimicrob Resist Infect Control. 2019;8:13.
Purpose This study aims to determine the effectiveness of anAntimicrobial Stewardship Program based on a Clinical Pathway (CP) to improve appropriateness in perioperative antibiotic prophylaxis (PAP).
Materials and Methods This pre-post quasi-experimental study was conducted in a 12 month period (six months before and six months after CP implementation),
2018
Authors: Hufnagel M, Versporten A, Bielicki J, et al.; for ARPEC Project Group.
Published in: J Pediatric Infect Dis Soc. 2018. doi: 10.1093/jpids/piy019.
Background This study was conducted to assess the variation in prescription practices for systemic antimicrobial agents used for prophylaxis among pediatric patients hospitalized in 41 countries worldwide.
Methods Using the standardized Antibiotic Resistance and Prescribing inEuropean Children Point Prevalence Survey protocol,
2018
Authors: Dona D, Baraldi M, Brigadoi G, et al.
Published in: Pediatr Infect Dis J. 2018;37(9):901-907.
Background Although Italian pediatric antimicrobial prescription rates are among the highest in Europe, little action has been taken to improve the appropriateness of antimicrobial prescriptions. The primary aim of this study was to assess changes in antibiotic prescription before and after acute otitis media (AOM) and group A streptococcus (GAS) pharyngitis Clinical Pathway (CP) implementation;
2018
Authors: Germovesk E, Lutsar I, Kipepr K, et al.; for NeoMero Consortium
Published in: J Antimicrob Chemother. 2018;73(7):1908-1916
Background Sepsis and bacterial meningitis are major causes of mortality and morbidity in neonates and infants. Meropenem a broad-spectrum antibiotic, is not licensed for use in neonates and infants below 3 months of age and sufficient information on its plasma and CSF disposition and dosing in neonates and infants is lacking.
2018
Authors: Tacconelli E, Sifakis F, Harbarth S, et al; for EPI-Net COMBACTE-MAGNET Group
Published in: Lancet Infect Dis. 2018;18(3):e99-e106.
Abstract Antimicrobial resistance poses a growing threat to public health and the provision of health care. Its surveillance should provide up-to-date and relevant information to monitor the appropriateness of therapy guidelines, antibiotic formulary, antibiotic stewardship programmes, public health interventions,
2018
Authors: Donà D, Zingarella S, Gastaldi A, et al.
Published in: PLoS One. 2018;13(2):e0193581.
Background Italian pediatric antimicrobial prescription rates are among the highest in Europe. As a first step in an Antimicrobial Stewardship Program, we implemented a Clinical Pathway (CP) for Community Acquired Pneumonia with the aim of decreasing overall prescription of antibiotics, especially broad-spectrum.
Materials and Methods The CP was implemented on 10/01/2015.
2016
Authors: Ramos-Martin R , Johnson A, Livermore J, et al.
Published in: J Antimicrob Ther 2016;71(4):992-1002